Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Medifast, Inc.NYSE: MED
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows in line with its trailing trend
Q1 FY2026 weighted avg shares of 11.01M shares rose 0.5% year over year, in line with the +0.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Weighted avg shares increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +0.5% holds above the trailing-twelve-month pace of +0.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 10.98M USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- -1.6%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.98M | +0.5% |
| FY2024 | 2024-12-31 | 10.93M | +0.4% |
| FY2023 | 2023-12-31 | 10.88M | -2.8% |
| FY2022 | 2022-12-31 | 11.2M | -4.4% |
| FY2021 | 2021-12-31 | 11.71M | — |
Weighted Avg Shares vs competitors
How MED compares with its peers on the latest reported figures
- MED's LTM Mar 2026 weighted avg shares of 10.99M shares is the 6th highest of the 10 companies compared; the peer median is 15.8M shares.
- Its year-over-year change of +0.5% is the 3rd highest of 10, against a peer median of -0.2%.
- Over three fiscal years its annual growth of -0.6% compares with a peer median of -0.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM May 2026 | 100.06M | -4.4% | -0.9% | |
| LTM Mar 2026 | 38.4M | +0.2% | +11.1% | |
| LTM Mar 2026 | 36.09M | -1.9% | -2.1% | |
| LTM Dec 2025 | 30.17M | -0.0% | -0.5% | |
AIIORobo.ai Inc. | FY2025 | 15.8M | +8.1% | +8.7% |
| LTM Mar 2026 | 10.99M | +0.5% | -0.6% | |
| LTM Mar 2026 | 10.75M | +1.4% | -0.0% | |
| LTM Feb 2026 | 8.68M | -0.7% | -2.6% | |
| LTM Jan 2026 | 2.86M | -0.2% | +0.9% | |
| FY2025 | 0 | -100.0% | — | |
| Peer median (excluding MED) | 15.8M | -0.2% | -0.3% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.